Your browser doesn't support javascript.
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test.
Heggestad, Jacob T; Kinnamon, David S; Olson, Lyra B; Liu, Jason; Kelly, Garrett; Wall, Simone A; Oshabaheebwa, Solomon; Quinn, Zachary; Fontes, Cassio M; Joh, Daniel Y; Hucknall, Angus M; Pieper, Carl; Anderson, Jack G; Naqvi, Ibtehaj A; Chen, Lingye; Que, Loretta G; Oguin, Thomas; Nair, Smita K; Sullenger, Bruce A; Woods, Christopher W; Burke, Thomas W; Sempowski, Gregory D; Kraft, Bryan D; Chilkoti, Ashutosh.
  • Heggestad JT; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Kinnamon DS; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Olson LB; Duke Medical Scientist Training Program, Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Liu J; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Kelly G; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Wall SA; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Oshabaheebwa S; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Quinn Z; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Fontes CM; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Joh DY; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Hucknall AM; Division of Plastic, Maxillofacial, and Oral Surgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
  • Pieper C; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Anderson JG; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27708, USA.
  • Naqvi IA; Center for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27710, USA.
  • Chen L; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Que LG; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
  • Oguin T; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
  • Nair SK; Department of Medicine and Duke Human Vaccine Institute, School of Medicine, Duke University, Durham, NC 27710, USA.
  • Sullenger BA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Woods CW; Department of Neurosurgery and Pathology, Duke University School of Medicine, Duke University, Durham, NC 27710, USA.
  • Burke TW; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC 27708, USA.
  • Sempowski GD; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Kraft BD; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Chilkoti A; Center for Applied Genomics and Precision Medicine, Department of Medicine, Duke University, Durham, NC 27710, USA.
Sci Adv ; 7(26)2021 06.
Article in English | MEDLINE | ID: covidwho-1282047
ABSTRACT
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 µl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abg4901

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Point-of-Care Testing / COVID-19 Serological Testing / SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: Sciadv.abg4901